linjc16/ctgov huggingface dataset:
Comparison of Dexmedetomidine and Propofol on the Delirium and Neuroinflammation in Patients With SIRS.

Study Overview
=================
Brief Summary
-----------------
Assessment of sedative effects of dexmedetomidine and propofol on the clinical course of delirium and neuroinflammation in patients with SIRS using CAM-ICU scale and protein S100b in serum.

Official Title
-----------------
Comparison of Sedative Effects of Dexmedetomidine and Propofol on the Clinical Course of Delirium and Neuroinflammation in Patients With SIRS.

Conditions
-----------------
Delirium

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine
* Drug: Propofol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presence of delirium Exclusion Criteria: presence of Alzheimer's disease any mental disorder presence of cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: dexmedetomidine<br>Treatment of delirium by dexmedetomidine i.v. infusion | Drug: Dexmedetomidine<br>* Treatment of delirium by dexmedetomidine i.v. infusion<br>* Other names: Dexdor;|
| Active Comparator: propofol<br>Treatment of delirium by propofol i.v. infusion | Drug: Propofol<br>* Treatment of delirium by Propofol i.v. infusion<br>* Other names: Diprivan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CAM-ICU scale |  | up to 5 days |
Clinical Pharmacist Anticoagulant Stewardship

Study Overview
=================
Brief Summary
-----------------
Initiative to improve direct anticoagulant utilization involving programmatic review by clinical pharmacists in collaboration with multidisciplinary team.

Detailed Description
-----------------
The Hadassah Hebrew University Medical Centers' Clinical Pharmacy team initiated a hospital-wide program, in collaboration with the institutions' coagulation specialists, including two hematologists and a clinical pharmacologist, for monitoring and promoting safe and effective prescription of direct oral anticoagulants (DOAC) during hospitalization. Electronic medical records throughout the hospital are screened for DOAC orders. All DOAC orders are assessed by a clinical pharmacist for potentially-inappropriate prescribing. When potentially-inappropriate prescribing or a drug-related problem is identified, the clinical pharmacist provided consultation on management options. In specific cases, additional guidance is provided by coagulation specialists. Consultations are recorded in the electronic medical record. Performance measures are collected and summarized.

Official Title
-----------------
Clinical Pharmacist Led Hospital-Wide Direct Oral Anticoagulant Stewardship Program

Conditions
-----------------
Safety Issues, Anticoagulant Toxicity

Intervention / Treatment
-----------------
* Other: Clinical Pharmacist Medication Review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients hospitalized in Hadassah Medical Center with a physician's order for direct oral anticoagulants (apixaban, rivaroxaban, or dabigatran). Exclusion Criteria: Patients hospitalized in departments without computerized physician order entry.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Clinical Pharmacist Medication Review|Programmatic review of physician orders for direct anticoagulants by clinical pharmacists.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of clinical pharmacist consultations accepted by attending physician. | Calculated by dividing the number of clinical pharmacist consultations accepted, by the number of clinical pharmacist consultations given, during the period. Data for consultation counts will be obtained from patient electronic medical record. | At forty-eight months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of clinical pharmacist consultations accepted by attending physician. | Calculated by dividing the number of clinical pharmacist consultations accepted, by the number of clinical pharmacist consultations given, during the period. Data for consultation counts will be obtained from patient electronic medical record. | At six months |
Cognitive Characteristics of PTSD Patients With OCD

Study Overview
=================
Brief Summary
-----------------
Cognitive profile of patients who suffer both from PTSD and OCD, as compared to those who suffer from PTSD or OCD without other comorbidity.

Detailed Description
-----------------
Demographic data and cognitive data will be compared on PTSD, PTSD-OCD and OCD patients using a battery of computerized cognitive tests

Official Title
-----------------
Cognitive Characteristics of PTSD Patients With OCD

Conditions
-----------------
Post-Traumatic Stress Disorders, Obsessive-Compulsive Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients suffer from current PTSD with no other co-morbidity Patients suffer from current OCD with no other co-morbidity Patients suffer from current PTSD and OCD Exclusion Criteria: Patients suffer from PTSD and OC symptoms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PTSD<br>Patients with diagnosis of PTSD | |
| OCD<br>Patients with diagnosis of OCD | |
| PTSD/OCD<br>Patients with diagnosis of comorbid PTSD and OCD | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Randomized, Double-Blind, Placebo-Controlled, With PHX1149 in Patients With Type 2 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
This will be a 4-week, multicenter, randomized, double-blind, parallel group, placebo-controlled, safety, tolerability, and efficacy study. Patients will be screened and be on one of three doses of PHX1149 (a new drug candidate for the treatment of Type 2 diabetes ) or placebo. The drug is a DPP4 inhibitor

Official Title
-----------------
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine Safety and Establish Proof of Concept With PHX1149 in Patients With Type 2 Diabetes Mellitus

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: PHX1149


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes mellitus treatment with metformin +/- TZD Exclusion Criteria: Type 1 diabetes mellitus

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 4<br> | Drug: PHX1149<br> <br> |
| Placebo Comparator: 3 active, 1 placebo<br> | Drug: PHX1149<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postprandial blood glucose |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fasting blood glucose, HbA1c, safety |  |  |
Collection of the Thrombo-VaxCov Cohort

Study Overview
=================
Brief Summary
-----------------
In the context of anti-Covid19 vaccination, atypical thrombosis have occured and potential link with vaccination is under investigation. This study collect clinical and biological data of all atypical thrombosis occurring within 4 weeks after antiCovid vaccination.

Detailed Description
-----------------
In the context of anti-Covid19 vaccination, atypical thrombosis have occurred and potential links with vaccination is under investigation. In France, the study collect clinical and biological data of all atypical thrombosis occurring within 4 weeks after anti-Covid vaccination.

Official Title
-----------------
A Clinico-biological Database on Atypical Venous Thrombosis in the Context of anticovid19 Vaccination

Conditions
-----------------
Covid19, SARS-CoV Infection, Venous Thrombosis, Thrombocytopenia, Vaccination; Complications

Intervention / Treatment
-----------------
* Other: Retrospective data and biological samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: atypical thrombosis symptoms onset within 4 weeks of vaccination Exclusion Criteria: children

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination<br> | Other: Retrospective data and biological samples<br>* Analysis of data and biological samples collected during hospitalization:<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional outcome (modified rankin scale) |  | through study completion, an average of 1 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrent vascular events |  | through study completion, an average of 1 years | 
| Mortality |  | through study completion, an average of 1 years |
A Comparison Between Deep Sclerectomy and Trabeculectomy

Study Overview
=================
Brief Summary
-----------------
Patients affected by medically uncontrolled open angle glaucoma will be randomised to either a non penetrating procedure (deep sclerectomy) or conventional trabeculectomy. The longterm efficacy (i.e. IOP w/out therapy) and safety (i.e. visual acuity, visual field stability and co-morbidities) will be evaluated.

Detailed Description
-----------------
Prospective 7-year randomised investigator -masked clinical trial 79 eyes (79 patients) enrolled randomised to surgery by PEX and previous pilocarpine use Deep sclerectomy n = 41 Trabeculectomy n = 38 Estimated DS : TE success = 1:3 10% attrition ; power = 90%, alpha = 5% Methods and evaluation of outcomes: IOP: average of the two highest readings of the IOP phasing (6 readings) VA: LogMAR (ETDRS chart) Lens: LOCSII (slit lamp classification), worsening = one step progression confirmed at two visits study visits: every 4 months

Official Title
-----------------
Deep Sclerectomy Versus Trabeculectomy. A 7 Year Prospective Randomised Clinical Trial

Conditions
-----------------
Glaucoma

Intervention / Treatment
-----------------
* Procedure: trabeculectomy
* Procedure: deep sclerectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Angle wide open Age > 65 yrs IOP > 23 and < 30 mmHg (average of the two highest readings of the daily IOP phasing) Topical beta blocker in fellow eye At least two medications in use + previous ALT MD < 20 dB (HFA 24-2 full threshold) LOCSII < C1-N1-P0

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: TE<br>trabeculectomy | Procedure: trabeculectomy<br>* Cairns-like trabeculectomy, limbus based, with 5_FU supplementation and argon laser suturelysis<br>|
| Experimental: DS<br>deep sclerectomy | Procedure: deep sclerectomy<br>* deep sclerectomy with no implant and no sutures to the superficial flap, limbus based with suppplementation of FU (if needed)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intra ocular pressure without therapy (% of eyes within pre-selected cut-off limits) |  | 7 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| (a) LogMAR visual acuity, (b) number of cataract extraction procedures |  | 7 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glaucoma, surgery, non penetrating procedures, cataract
A Search for Helicobacter Pylori in Localized Vulvodynia

Study Overview
=================
Brief Summary
-----------------
Hypothesis: to examine a possible association between localized vulvodynia and H. pylori infection.

Detailed Description
-----------------
Subsequent sections from the paraffin blocks were prepared and stained by modified Giemsa. Immunostaining for H. pylori was done as described. In short, tissue sections were deparaffinized in xylene, rehydrated through decreasing concentrations of alcohol ending in phosphate-buffered saline (PBS), and subjected to pretreatment with Proteinase K (8 minutes). The sections were quenched with 3% hydrogen peroxidase, incubated with protein block for 15 minutes at room temperature, and washed in PBS. Tissues then were incubated with polyclonal rabbit anti-H pylori antibody (dilution, 1:10; clone ch-20 429, DAKO, Carpinteria, CA). Finally, sections were washed in 0.05% polysorbate 20 in PBS, pH 7.4, and the bound antibody was detected using streptavidin and biotinylated secondary antibody with diaminobenzidine as the chromogen. Sections were counterstained with hematoxylin, dehydrated, and mounted. Negative controls were sections treated as above, but instead of incubation with the primary antibody, they were incubated with 1% bovine serum albumin in PBS. Vulvar biopsies of seven other women without localized vulvodynia served as healthy controls. The positive and negative control gastric tissues for the immunohistochemical stain of the H. pylori microorganisms were obtained from the archives of the Department of Pathology.

Official Title
-----------------
A Laboratory and Clinical Search for the Presence of H. Pylori and Treatment Against it in Localized Vulvodynia (Vestibulitis, Vestibulodynia).

Conditions
-----------------
Vulvodynia, Vulvar Vestibulitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Paraffin blocks of vestibular tissues from patients with Vestibulodynia Exclusion Criteria: Patients without vestibulodynia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Localized vulvodynia, Helicobacter pylori, peptic disease, omeprazole
The Impact of Using Triclosan-antibacterial Sutures on the Incidence of Surgical Site Infection

Study Overview
=================
Brief Summary
-----------------
To compare conventional polyglactin 910 sutures with triclosan-coated polyglactin 910 antimicrobial sutures for the reduction of surgical site infections and any associated health and economic benefits.

Official Title
-----------------
The Impact of Using Triclosan-antibacterial Sutures on the Incidence of Surgical Site Infection Prospective, Randomized, Controlled, Double Blind, Multi-centre Study.

Conditions
-----------------
Surgical Site Infection

Intervention / Treatment
-----------------
* Other: Vicryl Plus
* Other: Vicryl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients of different age Gender Risk factors and procedures candidate for surgical intervention during the period of the study Exclusion Criteria: Patients with an established pre-operative infection at the operative site
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Study group<br>The study group in which Triclosan-coated polyglactin 910 antimicrobial sutures will be used. | Other: Vicryl Plus<br>* Triclosan-coated polyglactin 910 antimicrobial sutures (Vicryl Plus)<br>* Other names: Triclosan-coated polyglactin 910 antimicrobial sutures;|
| Active Comparator: Control group<br>The control group in which polyglactin 910 antimicrobial sutures will be used. | Other: Vicryl<br>* Polyglactin 910 antimicrobial sutures (Vicryl)<br>* Other names: Polyglactin 910 antimicrobial sutures;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Signs of Surgical Site Infections (SSI) according to Centers for Disease Control (CDC) criteria |  | 30 days (or 1 year in case of prosthesis) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-operative hospital stay in days |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Surgical site infection, Antimicrobial triclosan-coated polyglactin 910 suture, Length of hospital stay, SSI
The Effect of Surfactant Administration on Cerebral Oxygenation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess changes in cerebral oxygenation during two different types (beractant and poractant) and two different routes (double lumen or single lumen endotracheal tube) of surfactant administration using near infrared spectroscopy (NIRS).

Official Title
-----------------
The Effect of the Type and the Method of Surfactant Administration on Oxygenation in Preterm Infants: a Near Infrared Spectroscopy Study

Conditions
-----------------
Respiratory Distress Syndrome, Prematurity

Intervention / Treatment
-----------------
* Device: near infrared spectroscopy (INVOS 5100)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of respiratory distress syndrome <32 gestational weeks and/or <1500 g birthweight Exclusion Criteria: major congenital anomalies complex congenital heart diseases

Ages Eligible for Study
-----------------
Minimum Age: 23 Weeks
Maximum Age: 32 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group 1, group 2, group 3, group 4<br>administration of beractant with single lumen ET tube administration of poractant with single lumen ET tube administration of beractant with double lumen ET tube administration of poractant with double lumen ET tube | Device: near infrared spectroscopy (INVOS 5100)<br>* monitorization of cerebral oxygenation by INVOS 5100 during surfactant administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to determine the optimal and the most safe surfactant administration technique with regard to cerebral oxygenation as measured by near infrared spectroscopy in low birth weigh infants |  | up to 36 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
RDS, surfactant, cerebral oxygenation, near infrared spectroscopy
Dexmedetomidine Pharmacokinetics During Continuous Renal Replacement Therapy (CRRT)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine dexmedetomidine pharmacokinetics during continuous renal replacement therapy on critically ill patients.

Detailed Description
-----------------
Dexmedetomidine is a selective alpha-2-adrenergic agonist with sedative properties indicated for sedation of patients in the intensive care setting. ICU patients with acute kidney injury requiring renal replacement therapies frequently have changes in volume status causing alterations in drug pharmacokinetics. Although dexmedetomidine pharmacokinetics have been studied earlier on ICU patients, there is no information on its pharmacokinetics in critically ill patients needing continuous renal replacement therapy.

Official Title
-----------------
Dexmedetomidine Pharmacokinetics During Continuous Venovenous Hemodialysis in Critically Ill Patients

Conditions
-----------------
Acute Kidney Injury

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 Clinical need for sedation Acute kidney injury requiring renal replacement therapy (according to ICUs standard operating procedures) Exclusion Criteria: Severe bradycardia (HR < 50/min) AV conduction block II-III (unless pacemaker installed) Severe hepatic impairment (bilirubin > 101 umol/l) Pregnancy or lactation Age < 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: dexmedetomidine<br> | Drug: Dexmedetomidine<br>* Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dexmedetomidine clearance by continuous venovenous hemodialysis |  | 10 hours from the start of the dexmedetomidine infusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dexmedetomidine, pharmacokinetics, critical illness, continuous renal replacement therapy